FDA Drug recall D-1185-2014
Tivicay (dolutegravir) Tablets 50 mg, 30 Tablet Bottles, Rx Only
- FDA Drug
- Class III
- terminated
- Published 2014-04-09
On 2014-04-09 the FDA classified a Class III recall of Tivicay (dolutegravir) Tablets 50 mg, 30 Tablet Bottles, Rx Only by Viiv Healthcare, citing cross Contamination with Other Products: Product contains Promacta (eltrombopag).
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1185-2014 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2014-02-11 |
| Published | 2014-04-09 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Viiv Healthcare |
| Distribution | US |
Product
Tivicay (dolutegravir) Tablets 50 mg, 30 Tablet Bottles, Rx Only. Manufactured for: ViiV Health, TRP, NC 27709; by: GlaxoSmithKline, Research Triangle Park, NC 27709. Made in Japan. NDC 49702-228-13
Reason
Cross Contamination with Other Products: Product contains Promacta (eltrombopag).
Identifiers
| ndc | 49702-255-37 |
|---|---|
| ndc | 49702-226-13 |
| ndc | 49702-227-13 |
| ndc | 49702-228-13 |
| code_info | Lot #: 3ZP2210 Sub-lot A, Expiry: 10/15 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1185-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.